http://web.archive.org/web/20141101010153id_/http://www.dailymail.co.uk/health/article-2736278/Drug-hope-Crohn-s-patients-New-treatment-work-gut-target-symptoms-disease.html

a new drug could bring relief for the 250,000 @entity2 who have the serious bowel disorder @entity3			0
@entity4 is the first to work directly in the gut lining , targeting the inflammation that causes chronic symptoms such as diarrhoea , bleeding and fatigue			1
in trials , 40 per cent of patients were free of symptoms for at least a year – with healing of the gut lining in some cases			1
scroll down to video a new drug could bring hope to @entity3 's disease patient 's after the treatment is the first to work in the gut @entity4 is the biggest advance since drugs known as anti-tnfs were developed in the 1990s			1
researchers at @entity26 say the new treatment , a course of which costs about £ 12,000 a year , brings ‘ additional options ’			2
the disease may be diagnosed at any age , but it tends to strike early in life			0
sufferers have periods of good health as well as times when symptoms are more active , known as relapses or flare - ups			0
trial data shows that 40 per cent of patients taking the new treatment are free of symptoms for at least one year , with healing of the gut lining in some sufferers			1
twice as many @entity3 ’s patients were symptom - free as those being treated with a dummy drug , according to trial data on 2,700 patients from centres including @entity53 , @entity54 and @entity55			0
the drug made by @entity57 – based @entity58 is the first of its kind , given by infusion every eight weeks , and a major advance since biologic drugs known as anti-tnfs were developed in the late 1990s			2
in trials 40 per cent of patients were free of symptoms for at least a year and gut was healed in some cases dr @entity70 , @entity71 and @entity2 principal @entity72 said ‘ over a decade ago , the introduction of anti-tnfs improved the management of @entity77 and @entity78 in patients with moderate to severe disease			1
‘ now , for these patients who can face a lifetime of chronic symptoms , vedolizumab offers an additional treatment option with a completely new mode of action that specifically targets inflammation in the gut lining			1
’ many @entity3 ’s patients do not respond to current treatments , or the effects rapidly wear off , and they face major surgery at a very young age			0
a lifetime of treatment is estimated to cost the @entity96 up to £ 720 million per year , which puts the financial burden on par with other chronic diseases such as diabetes and cancer			0
researchers at @entity26 say a course of the new treatment costs about £ 12,000 a year			2

@entity4 is first to work directly in gut lining targeting inflammation
in trials 40 per cent of patients were free of symptoms for at least a year
it is biggest advance since 1990s when drugs anti-tnfs were developed
a course of new treatment is *thought* to cost around £ 12,000 a year

@entity3:Crohn
@entity2:UK
@entity26:Barts Health NHS Trust
@entity4:Vedolizumab
@entity53:London
@entity57:Japan
@entity78:CD
@entity55:Cardiff
@entity54:Cambridge
@entity96:NHS
@entity77:UC
@entity58:Takeda UK
@entity71:Consultant Gastroenterologist
@entity70:James Lindsay
@entity72:Clinical Trial Investigator , Barts and the London NHS Trust